Antibiotic Treatment of Pulmonary Infections: An Umbrella Review and Evidence Map

Abstract

Background: Considering the global burden of pulmonary infections, there is an urgent need for optimal empirical antimicrobial therapy strategies for pulmonary infections, which should rely on reliable evidence. Therefore, we aim to investigate the optimal treatment options for pulmonary infections in adults and assess the strength of that evidence.Methods: We searched PubMed, Embase, the Cochrane Library, and China Biology Medicine disc to identify systematic reviews and meta-analyses of randomized controlled trials (RCTs) focusing on antimicrobial treatments for pulmonary infections. The outcomes of the included meta-analyses should include all-cause mortality or clinical treatment success. For each meta-analysis, we estimated relative risk (RR) with 95% CI. We also created an evidence map to show the efficacy of each antimicrobial treatment strategy and the certainty of the evidence.Results: Twenty-six meta-analyses and two new RCTs were included that contained 31 types of antimicrobial therapy strategies. We found that carbapenems were related to lower mortality than other β-lactams or fluoroquinolones alone or in combination with aminoglycosides for HAP patients (RR 0.76, 95% CI: 0.58–0.99). There was no statistical difference in all-cause mortality between the other antimicrobial therapy strategies. As for clinical cure, treatment with fluoroquinolones was associated with better success versus macrolides or β-lactams alone for CAP patients in both the intention-to-treat (ITT) population (RR 1.22, 95% CI: 1.02–1.47) and clinically evaluable (CE) population (RR 1.37, 95% CI: 1.11–1.68). Treatment with carbapenems showed a better clinical cure over non-carbapenems for VAP patients (RR 1.21, 95% CI: 1.05–1.4). Adjunctive inhaled antibiotics compared with intravenous antibiotics alone showed a benefit for VAP (RR 1.2, 95% CI: 1.05–1.35). In addition, adjunctive nebulized aminoglycoside for nosocomial pneumonia was associated with a higher cure rate versus intravenous antibiotics alone in the ITT population (RR 1.28, 95% CI: 1.04–1.57), while no statistical difference in clinical cure was observed between other intervention groups.Conclusions: We cannot evaluate which antibiotic is the best choice for the treatment of pulmonary infection. Carbapenems or adjunctive inhaled antibiotics showed a reasonable choice for HAP or VAP. However, we do not find a statistical difference between most antimicrobial therapy strategies for CAP patients.

Candent issues in pneumonia. Reflections from the Fifth Annual Meeting of Spanish Experts 2023

“…Recommended empiric antibiotic treatment can be read in table 2 . Guidelines worldwide recommend a combination of a beta-lactam plus macrolide or quinolone [ 29 , 96 – 98 ]. Due to potential serious adverse effects of quinolones [ 61 ] and proven benefits of macrolide combinations of 3 days, this last is the preferred option.…”

Does “all disease begin in the gut”? The gut-organ cross talk in the microbiome

“…Therapeutic approaches aimed at enhancing the lung microbiome for respiratory well-being are promising avenues for managing airway diseases. Studies have explored diverse strategies to modulate the lung microbiome, including probiotic supplementation, antimicrobial therapy, and microbiota transplantation (Mortaz et al 2013 ; Chmiel et al 2014 ; Jang et al 2020 ; Wu et al 2021 ; Du et al 2022 ). For example, Yeo et al ( 2014 ) demonstrated the potential of probiotics containing Lactobacillus fermentum CJL-112 strain to prevent influenza virus infection by activating the T-helper cells.…”

Untitled

“…Recommended empiric antibiotic treatment can be read in table 2. Guidelines worldwide recommend a combination of a beta-lactam plus macrolide or quinolone [29,[96][97][98]. Due to potential serious adverse effects of quinolones [61] and proven benefits of macrolide combinations of 3 days, this last is the preferred option.…”